New Bridge Venture Aligns With Takeda Externalization Strategy
Executive Summary
A new collaborative academic-industry medicines development venture involving Takeda has started operations in the US, aiming to smooth and speed the passage of basic research projects through clinical trials and eventually to the market.
You may also be interested in...
Entyvio Takes Lead As Takeda Pursues Turnaround
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
Refocus, Optimize, Externalize: Takeda Overhauls Global R&D
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.